Skip to content

Feed Screener Search Methodology

SEC · FI · BAFIN · AFM · AMF

Pricing Sign in

InsiderLens

Statistics predict. AI explains.

Insider transactions from public regulatory disclosures, aggregated and enriched with deterministic statistical signals. Not investment advice.

Sources

SEC EDGAR · US
FINANSINSPEKTIONEN · SE
BAFIN · DE
AFM · NL
AMF · FR

Product

Methodology
Privacy notice
Object to processing

Feed Screener Search Methodology

Pricing Sign in

Kasahara Noriyuki — 4D Molecular Therapeutics, Inc. insider: 2 transactions · InsiderLens

Home / Insiders / Kasahara Noriyuki

Kasahara Noriyuki

Director at 4D Molecular Therapeutics, Inc. · on record since Sep 27, 2022

Insider trading activity of Kasahara Noriyuki

Transactions on record: 2; since Sep 27, 2022

Open-market buys: 0

Open-market sells: 0

Companies traded: 1; last filing May 25, 2023

Figures computed from official regulatory filings — methodology.

Companies where Kasahara Noriyuki has traded

4D Molecular Therapeutics, Inc.2 tx · May 25, 2023

Track record of Kasahara Noriyuki

Insufficient history for a statistical track record (fewer than 5 open-market buys).

Transaction history of Kasahara Noriyuki

Co-insiders of Kasahara Noriyuki

BIOTECHNOLOGY VALUE FUND II LP4D Molecular Therapeutics, Inc.
BIOTECHNOLOGY VALUE FUND L P4D Molecular Therapeutics, Inc.
Biotechnology Value Trading Fund OS LP4D Molecular Therapeutics, Inc.
Bizily Scott4D Molecular Therapeutics, Inc.
Burkoth William T.4D Molecular Therapeutics, Inc.
BVF GP HOLDINGS LLC4D Molecular Therapeutics, Inc.
BVF I GP LLC4D Molecular Therapeutics, Inc.

This page republishes public regulatory disclosures. Concerned by this data? Exercise your right to object →

BVF II GP LLC4D Molecular Therapeutics, Inc.

BVF INC/IL4D Molecular Therapeutics, Inc.

BVF PARTNERS L P/IL4D Molecular Therapeutics, Inc.

BVF Partners OS Ltd.4D Molecular Therapeutics, Inc.

Chacko Jacob4D Molecular Therapeutics, Inc.

FISHMAN ROBERT S4D Molecular Therapeutics, Inc.

GRAY SUSANNAH4D Molecular Therapeutics, Inc.

Gupta Ashoo4D Molecular Therapeutics, Inc.

HALVORSEN OLE ANDREAS4D Molecular Therapeutics, Inc.

Humer Kristian4D Molecular Therapeutics, Inc.

Kamal Fariborz4D Molecular Therapeutics, Inc.

Kim Robert Young4D Molecular Therapeutics, Inc.

Kirn David4D Molecular Therapeutics, Inc.

Kolchinsky Peter4D Molecular Therapeutics, Inc.

LAMPERT MARK N4D Molecular Therapeutics, Inc.

Mehra Uneek4D Molecular Therapeutics, Inc.

Miller-Rich Nancy4D Molecular Therapeutics, Inc.

MILLIGAN JOHN F4D Molecular Therapeutics, Inc.

Moretti August J4D Molecular Therapeutics, Inc.

Ott David C.4D Molecular Therapeutics, Inc.

RA Capital Biotech Fund LP4D Molecular Therapeutics, Inc.

RA CAPITAL MANAGEMENT, LLC4D Molecular Therapeutics, Inc.

SBLENDORIO GLENN4D Molecular Therapeutics, Inc.

SCHAFFER DAVID4D Molecular Therapeutics, Inc.

Shabet Rose Sharon4D Molecular Therapeutics, Inc.

Shah Rajeev M.4D Molecular Therapeutics, Inc.

Simms Christopher Paul4D Molecular Therapeutics, Inc.

THEUER CHARLES4D Molecular Therapeutics, Inc.

Tomasello Shawn4D Molecular Therapeutics, Inc.

VIKING GLOBAL INVESTORS LP4D Molecular Therapeutics, Inc.

Viking Global Opportunities GP LLC4D Molecular Therapeutics, Inc.

Viking Global Opportunities Illiquid Investments Sub-Master LP4D Molecular Therapeutics, Inc.

Viking Global Opportunities Parent GP LLC4D Molecular Therapeutics, Inc.

Viking Global Opportunities Portfolio GP LLC4D Molecular Therapeutics, Inc.

YAO TONY DUNG LING4D Molecular Therapeutics, Inc.

Zimmermann Carolyne4D Molecular Therapeutics, Inc.

Company	Filed	Type	Qty	Price	Value · USD	Src
4D Molecular Therapeutics, Inc.	May 25, 2023	AwardD	22,500	0.00 USD	$0	SEC
4D Molecular Therapeutics, Inc.	Sep 27, 2022	AwardD	45,000	0.00 USD	$0	SEC